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ABSTRACT
Transplantation protocols for patients with Fanconi anemia are being modified continuously. However, it is
unclear how outcomes have changed over time. We determined historical adverse event rates from long-term
follow-up of 117 Fanconi anemia patients in the Hôpital Saint Louis transplant cohort, who received low-dose
cyclophosphamide- and irradiation-based conditioning, in combination with other modalities, between 1976
and October 2002. In high-risk patients with mismatched donors, the peritransplantation mortality rate during
0 to 6 months declined significantly over time (P  .003), from 28%/month (95% confidence interval [CI],
9%-87%/month) during 1985 to 1989 to 3.3%/month (95% CI, 0.8%-13.3%/month) during 2000 to October
2002. The corresponding proportion of patients who developed severe acute graft-versus-host disease also
declined significantly over time (P  .003). In low-risk patients with matched sibling donors, the peritrans-
plantation mortality rate was consistently low, 1.4%/month (95% CI, 0.3%-5.3%/month), during 1990 to
October 2002. Sample sizes to detect 2-fold reductions from rates and risks observed since the mid-1990s are
larger than recently reported case series. To demonstrate further advances in survival, transplant centers may
need to coordinate their protocols and engage in multicenter collaborative studies.
© 2005 American Society for Blood and Marrow Transplantation
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Fanconi anemia (FA) is a genetically heteroge-
eous genomic instability syndrome [1] associated
ith diverse congenital abnormalities, progressive
one marrow failure, acute myeloid leukemia, and
olid tumors [2]. Hematopoietic stem cell transplan-
ation is the only current therapy that can restore
ormal hematopoiesis in patients with FA. The cumu-
ative incidence of bone marrow transplantation,
eath secondary to progressive bone marrow failure,
r acute myeloid leukemia was 64% by age 48 years in
he North American Survey [3]; all of these patients
ither received a transplant or developed indications
or one. s
72It has been challenging to adapt protocols for
ransplantation to the setting of FA [4]. Because of
heir underlying defect in DNA repair, FA patients are
ypersensitive to treatment with irradiation and cyto-
oxic agents such as cyclophosphamide. Pretransplan-
ation conditioning regimens modiﬁed for FA patients
ave met with some success. At present, outcomes for
A patients with a matched sibling donor are quite
ood; however, results for patients with other donor
ypes are comparatively less successful [5]. Several
otential complications put patients at an increased
isk of early death, including acute and chronic graft-
ersus-host disease (aGVHD and cGVHD, respec-
ively). In long-term survivors, the incidence of
econdary solid tumors, particularly squamous cell
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Sample Size Calculations for Transplantation in FA
Bancers (SCC) of the head and neck, has been an
ngoing concern [6]. Severe aGVHD (grades III plus
V) and extensive cGVHD are associated with SCC in
atients who survive these transplantation complica-
ions [5,7].
There is considerable interest in novel improved
nd “gentler” transplantation protocols for FA pa-
ients to increase survival and decrease aGVHD,
GVHD, and, it is hoped, secondary SCC. Several
nnovations have been considered, including regimens
ith less or no irradiation or cyclophosphamide; new
onditioning agents such as antithymocyte globulin
ATG), ﬂudarabine (FLU), and Campath (Schering
lough, Oxford, UK); graft manipulations such as
D34 stem cell selection; and alternative sources of
tem cells rather than bone marrow [8-12].
Several of these innovations have been piloted or
ested in small patient series over the years, and stan-
ards of care have evolved to include some of these
odalities, such as ATG and FLU. However, it has
roven difﬁcult to determine the best approaches. The
ssue of statistical power is a fundamental problem.
ecause FA is a rare disease, transplantation protocols
or FA patients have been institution speciﬁc, each
ith a comparatively low rate of patient accrual, even
t the largest transplant centers. Consequently, these
tudies have not been randomized [13].
To help investigators who are planning future
ransplantation studies for FA patients, we asked 3
elated questions. First, have outcomes improved over
alendar time in concert with changes in the standards
f care? Second, what are the relevant study end
oints and corresponding historical control rates that
ight be used to evaluate emerging therapies? Third,
hat sample size is required to prove that a new
egimen is superior to a standard?
By necessity, historical control rates are needed to
alculate the statistical power at a given sample size.
or this purpose, we identiﬁed relevant study end
oints and determined historical control rates by using
ong-term follow-up of 117 FA patients who received
ransplants at the Hôpital Saint Louis (SLH) in Paris,
rance [5]. The SLH cohort is the largest published
eries of FA patients who had transplantations per-
ormed by a single team at a single institution. We also
erformed a literature review to determine the sample
izes of recently reported studies of FA patients who
eceived transplants and evaluated the power of these
tudies in light of our sample size calculations.
ETHODS
istorical Control Rates in SLH
We previously studied long-term follow-up of 117
A patients who received transplants at the SLH [5].
nalytical studies of a subset of these patients with s
B & M Tismatched [14] and matched [7] donors have also
een reported. Almost all of these patients were con-
itioned with low-dose cyclophosphamide and irradi-
tion. Several groups have adapted the original pro-
ocol for use in their own institutions. Similarly, SLH
rotocols have evolved over time to include other
odalities, including ATG and FLU. In this series of
17 patients, 5 received transplants in 1976 to 1979,
4 in 1980 to 1984, 15 in 1985 to 1989, 69 in the
990s, and 14 in 2000 to October 2002. We chose to
xclude from our analysis the earlier years 1976 to
984, because protocols and supportive care have ad-
anced considerably since then. Therefore, we pro-
ose here to use the SLH experience with 98 patients
ho received transplants during 1985 to October
002 as an indicator of trends over time in the ﬁeld as
whole, recognizing that both patients and protocols
re heterogeneous.
We stratiﬁed this cohort into groups of patients
ho received transplants during 4 calendar periods:
985 to 1989, 1990 to 1994, 1995 to 1999, and 2000 to
ctober 2002, henceforth “2000 to 2002.” On the
asis of our previous analysis, we considered 5 patient
roups and end points for analysis: the cumulative
ncidence of death at 6 months in patients with a
ismatched (matched unrelated or mismatched re-
ated) donor (high-risk patients) and in patients with a
atched sibling donor (low-risk patients); the cumu-
ative incidence of severe aGVHD at 100 days; and the
umulative incidence of SCC at 10 years. For the end
oint of peritransplantation mortality, we calculated
he mortality rate from tables of person-years and
umbers of deaths for the deﬁning 0- to 6-month
ollow-up interval according to patient group and the
alendar period of transplantation. For the end point
f severe aGVHD, we calculated the proportions of
atients who developed this complication during 0 to
00 days according to patient group and the calendar
eriod. Because the numbers of SCC cases were com-
aratively limited and the ﬁrst case appeared 5 years
fter transplantation, we calculated the cumulative in-
idence of SCC through 10 years in all patients who
eceived transplants during 1990 to 1999.
For the end point of peritransplantation mortality,
e examined rates and trends by using Poisson regres-
ion. For the end point of severe aGVHD, we exam-
ned risks and trends by using logistic regression. For
he end point of SCC, we considered the cumulative
ncidence at 10 years in the presence of competing
ortality. Finally, as a general indicator of advances in
rotocols, we tabulated the frequency of speciﬁc mo-
alities over time. Because the focus of this analysis is
alendar time trends and sample size calculations, we
id not examine the relationship between speciﬁc mo-
alities and outcomes for this article. Some of the
peciﬁc associations have been reported elsewhere [14].
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6ample Size Calculations
We computed the required sample size for a bi-
omial test comparing the cumulative incidence ob-
erved in a new series with the cumulative incidence
bserved in the SLH. We set the type I error rate
false-positive rate) to   .05. We set the type II
rror rate (false-negative rate) to   .20, correspond-
ng to 80% power. All tests were 2 sided. We deﬁned
ull and alternative hypotheses as follows. From SLH,
e obtained the monthly event rates 0. For example,
n the entire cohort, the monthly death rate during 0
o 6 months was 7.1%/month [5]. Assuming a con-
tant hazard rate, the cumulative mortality at land-
ark time T  6 months equals
p0 1 exp(0T ).
Suppose a new protocol is to be tested in the hope
hat it will cut the monthly death rate in half, from 0
o 1 (1 0/2). The factor of 1/2 corresponds to the
arameter , the treatment relative risk. A value of  
/2 represents a 2-fold reduction in the hazard,
hereas a value of   1/4 represents a 4-fold reduc-
ion, and so on. In this scenario, the cumulative mor-
ality will not be p0, but instead will be
p1 1 exp(0T ).
et n be the number of patients enrolled and followed
p through time T. Let X be the number who have the
vent “death during 0 to 6 months.” Under the null
ypothesis (H0) that a new protocol has the same
fﬁcacy as the SLH protocol, X follows the binomial
istribution X  Bin(n,p0). For sample size calcula-
ions, we ask how large n must be to reject H0 if X 
in(n,p1).
To compute the required sample size, we invoked
he normal approximation to the binomial distribution
nd applied the standard formula [15]:
n
p0q0z1⁄2 z1p1q1p0q0
2
(p1 p0).2
,
here q0  1  p0, q1  1  p1, and z	 is the 100(1 
) percentile of the standard normal distribution.
We also considered the reverse problem of deter-
ining the smallest detectable fold- reduction  for a
iven n. We computed these values as follows. First,
he critical values of the test under the null are
cL np0np0q0z1⁄2
nd
cU np0np0q0z1⁄2.
nder the alternative,Power(ZL) 1(ZU) , i
74here
Zj (cj np1) ⁄np1q1,
 L,U, and 
(.) is the cumulative standard normal
istribution. The values of power can be evaluated as
function of p1 with n and all other parameters ﬁxed.
he value of p1 that minimizes [Power(p1)  0.80]
2,
1,min, was found numerically (by using a golden
ection search and parabolic interpolation), and the
orresponding value
min log(1 p1,min) ⁄ log(1 p0)
or small n and p0, the expected number of events may
e fewer than 5, and the normal approximation may
ot be valid. In these instances, we calculated the
ritical values and power by using an exact binomial
est. All calculations were performed with MATLAB
ersion 7.0 (MathWorks, Natick, MA).
iterature Review
The medical literature was searched by using
EDLINE for all patients with FA who received a
ransplant. The search was supplemented after the
ibliographies of each publication were reviewed. The
nalysis was restricted to studies published between
999 and 2004. The search terms were “Fanconi’s
nemia,” “Fanconi anemia,” or “aplastic anemia.” In-
ormation about individual studies was entered into an
xcel spreadsheet (Microsoft, Redmond, WA), which
as used to tabulate characteristics of patient series
nd case reports.
ESULTS
rends in Transplantation
Transplantation protocols have advanced over
ime (Table 1), particularly for patients with a mis-
atched donor. Initially, almost all patients received
ow-dose cyclophosphamide and irradiation. In high-
isk patients with a mismatched donor, ATG was used
xtensively during 1995 to 2002, and FLU was used
xtensively during 2000 to 2002. These modalities
ere used in a smaller proportion of low-risk patients
ith a matched sibling donor.
istorical Control Rates in SLH
Among high-risk patients with mismatched do-
ors, the peritransplantation mortality rate during 0 to
months declined signiﬁcantly over time (P  .006;
igure 1A, left axis) from 28%/month (95% conﬁ-
ence interval [CI], 9%-87%/month) during 1985 to
989 to 3.3%/month (95% CI, 0.8%-13.3%/month)
uring 2000 to 2002. The period-speciﬁc rates are
ncertain (error bars in Figure 1A show correspond-
ng 95% CI). The ﬁtted rate declined by 1.8-fold
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Sample Size Calculations for Transplantation in FA
B95% CI, 1.2- to 2.8-fold) per period from 1985 to
989 through 2000 to 2002. In this group, the pro-
ortion of patients who developed severe aGVHD
lso declined signiﬁcantly over time (P  .003; Figure
C, left axis) from 50% (95% CI, 12.3%-87.7%) dur-
ng 1985 to 1989 to 7.7% (95% CI, 1.1%-39.1%)
uring 2000 to 2002.
Among low-risk patients with matched sibling do-
ors, the peritransplantation mortality rate during 0 to
months (Figure 1B, left axis) was 1.4%/month (95%
I, 0.3%-5.3%/month) during 1990 to 1999. There
ere no peritransplantation deaths among 6 low-risk
atients who received transplants during 1995 to 2002
rates for 1995 to 1999 and 2000 to 2002 were unsta-
le, and error bars are not shown). The trend over
ime was not signiﬁcant (P  .54). In this group, the
roportion of patients who developed severe aGVHD
Figure 1D, left axis) was stable over time (P  .71 for
rend). Among patients who received transplants dur-
ng 1990 to 1999, the proportion who developed se-
ere aGVHD was 17.9% (95% CI, 7.7%-36.4%).
nly 1 low-risk patient received a transplant during
000 to 2002; this patient did not develop severe
GVHD. Among patients who received transplants
uring 1990 to 1999, the cumulative incidence of SCC
y 10 years after transplantation was 15.2% (95% CI,
.6%-28.7%), similar to the ﬁgure of 12.1% (95% CI,
.7%-20.4%) observed in the entire SLH cohort.
ample Size Calculations
We computed the sample size required to detect a
-fold reduction in the peritransplantation mortality
able 1. Number of SLH Patients Who Received Transplants and Wer
Modality 1976-1984* 1985-1989
atched donor‡
ATG 1 0
FLU 0 0
BU 0 0
T-cell depletion 0 0
TBI 0 0
TLI 13 11
CY 16 11
n 16 11
ismatched donor
ATG 0 1
FLU 0 0
BU 0 0
T-cell depletion 0 0
TBI 0 1
TLI 1 3
CY 3 4
n 3 4
TG indicates antithymocyte globulin; FLU, ﬂudarabine; BU, b
CY, cyclophosphamide.
These patients are not included in this analysis.
January 2000 through October 2002.
Matched donor is an HLA-identical sibling; mismatched donor isate in high-risk patients (Figure 1A, right axis) and l
B & M Tow-risk patients (Figure 1B, right axis) with 80%
ower, allowing for a 5% false-positive rate. The re-
uired sample size increases at a greater than linear
ate as the benchmark rate declines; here, the bench-
ark rate equals the ﬁtted or smoothed rate that
llows for a calendar time trend (Figure 1A and B,
ight axes; dotted blue curves). According to these
alculations, 84 high-risk patients, each followed up
or 6 months, would sufﬁce to detect a 2-fold rate
eduction when the benchmark rate equals 5.5%/
onth, corresponding to the ﬁtted rate for the 2000 to
002 period. A smaller number of high-risk patients (n
49), would sufﬁce when the appropriate benchmark
ate equals 10.0%/month, the ﬁtted rate for the 1995
o 1999 period. In contrast, 351 low-risk patients
ould be needed to detect a 2-fold reduction from the
tted rate in 1990 to 1994 of 1.3%/month, because
arly deaths are expected to be comparatively rare.
he required sample size increases rapidly as the
enchmark rate declines below the value of 1.3%/
onth.
Next, we computed the sample size required to
etect a 2-fold reduction in the risk of severe aGVHD
n high-risk (Figure 1C, right axis) and low-risk (Fig-
re 1D, right axis) patients. The proportion of low-
isk patients who developed severe aGVHD was stable
ver time (Figure 1D, left axis), whereas the propor-
ion of high-risk patients who developed this compli-
ation declined to a similar level by the mid-1990s. If
he proportion of patients expected to develop this
omplication were 15.0% (the time-averaged value for
ed with Selected Modalities, by Calendar Period
1990-1994 1995-1999 2000-2002†
2 1 0
0 0 1
0 1 0
0 0 0
0 0 0
23 4 0
23 5 1
23 5 1
4 23 9
9 0 12
1 1 7
0 18 0
0 21 4
16 2 0
17 24 9
17 24 13
n; TBI, total body irradiation; TLI, total lymphoid irradiation;
er donor types.e Treat
usulfaow-risk patients, shown by the horizontal dotted blue
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6urve in Figure 1D, right axis), then 165 patients
ould be required.
The same number of patients, 165, is needed to
etect a 2-fold reduction in the estimated 10-year
ncidence of SCC, because the cumulative incidence is
imilar in magnitude: 15.2% at 10 years versus 15.0%
t 100 days. This latter calculation implicitly assumes
hat the competing risk of death would be the same as
hat was observed in SLH patients who received
ransplants during the 1990s. If the competing risk of
eath were lower, then more patients would live long
nough to develop SCC, and the power of the study
ould be higher. However, it would be optimistic to
lan a study on the basis of such an assumption.
Finally, we computed the detectable fold- reduc-
ion for a given n at 80% power, allowing for a 5%
alse-positive rate, for selected benchmark values (Ta-
le 2). Notably, with as few as 25 high-risk patients
ith mismatched donors, each followed up for 6
onths, a 2.8-fold reduction in the peritransplanta-
ion mortality rate could be detected with 80% power.
larger number of patients (n  100) is required to
igure 1. Secular trends in peritransplantation mortality and se
emonstrate 2-fold risk reductions. (A, left axis, blue) Monthly mo
ismatched donor by calendar period. Observed rates (data points) w
dot-dash curve) are shown. (A, right axis, red, dashed curve) Corres
he ﬁtted rate with 80% power, allowing for a 5% false-positive rate
eduction (right axis) in patients with a matched donor. Note the ch
oints, error bars, and dot-dash curve) Proportion of patients with
C, right axis, red, dashed curve) Sample size required to detect a 2-
ith a matched donor who developed severe aGVHD and the cor
roportion is constant over time. m indicates months.etect a similar 2.6-fold reduction in the risk of severe
76GVHD, because the cumulative incidence of this
omplication is comparatively lower (15% versus
5%). The same number of patients, each followed up
or 10 years, would likely detect a 2.6-fold reduction
n the cumulative incidence of SCC.
iterature Review
We found 33 studies of 251 patients (Table 3).
he largest 7 studies had from 8 to 69 patients. An
dditional 26 studies each had from 1 to 4 patients. Of
hese, 15 were single case reports. Of 251 patients, 129
51%) received stem cells (usually derived from bone
arrow) from a matched sibling, and 122 (49%) re-
eived stem cells from other types of donors (mis-
atched). The conditioning regimens were heteroge-
eous. Two hundred eight patients (83%) were
onditioned with irradiation, and 24 (10%) were con-
itioned with FLU. ATG was used in 80 patients,
usulfan in 4, Campath in 2, T-cell depletion in 59,
nd CD34 stem cell selection in 13. No study used
andomization.
VHD in SLH and the corresponding sample sizes needed to
rate during the 0- to 6-month follow-up period in patients with a
% CI (error bars) and ﬁtted rates allowing for a calendar time trend
g sample size required to demonstrate a 2-fold rate reduction from
onthly mortality rate (left axis) and sample size to detect 2-fold rate
the y-axis scale between A and B (left axes). (C, left axis, blue, data
atched donor who developed severe aGVHD, by calendar period.
sk reduction from the ﬁtted proportion. (D) Proportion of patients
ding sample size to detect 2-fold risk reduction. In (D), the ﬁttedvere aG
rtality
ith 95
pondin
. (B) M
ange in
a mism
fold ri
responExcluding SLH, the largest reported series in
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Sample Size Calculations for Transplantation in FA
B999 to 2004 had 29 patients. As shown in Table 2,
tudies of this size are powered to detect major im-
rovements but are unlikely to detect a 2-fold reduc-
ion in the rate of any end point shown in Figure 1 or
able 2.
ISCUSSION
Continuous improvements in outcomes (Figure 1)
re presumably related to improvements in protocols
Table 1) and in supportive care. In FA patients with
ismatched donors, the peritransplantation mortality
ate signiﬁcantly and substantially declined over time,
ecreasing by approximately 1.8-fold in each of 4
onsecutive calendar periods. In the most recent pe-
iod studied, January 2000 to October 2002, the rate
ad declined to 3.3%/month. The precise value of this
ate is uncertain; however, it clearly represents a dra-
atic decrease from the rate of 28%/month that held
uring 1985 to 1989. Overall, the data show a trend
oward convergence of results that can be obtained for
atients with mismatched and matched donors.
able 2. Detectable-Fold Reduction for a Given Sample Size
End Point
Cumulat
Incidenc
ortality 0-6 mo, mismatched donor, 1995-1999
referent 45% at 6
ortality 0-6 mo, mismatched donor, 2000-2002
referent 28% at 6
ortality 0-6 mo, matched donor, 1990-1999
referent 7.8% at 6
evere aGVHD, matched/mismatched donor,
1995-1999 referent 15.0% at 1
CC, 1990-1999 referent 15.2% at 1
Values were computed with the exact binomial test. Because of th
is not a continuous function of n or of the cumulative incidenc
able 3. Published Patient Series and Case Reports of Fanconi Anemia
Study* Year of Report
e Medeiros: Brazil [11] 1999
ufour: Italy AIEOP-GITMO [16] 2001
yas: Saudi Arabia [17] 2001
uardiola: Paris [7]‡ 2004
5 studies, 1-4 patients§ 1999-2004
acMillan: Minnesota [18] 2000
uardiola: Europe [14]‡ 2000
oyer: Cincinnati [9] 2003
1 studies, 1-4 patients 1999-2004
3 studies 1999-2004
These 33 patient series or single case reports with matched or mi
matched and mismatched patients in the same publication; thes
N indicates the total number of subjects; XRT, the number who
conditioning with ﬂudarabine.
These series include patients from the SLH cohort.
Seven of these 15 studies are single case reports.
Eight of these 11 studies are single case reports.
B & M TThe demonstrated progress in this ﬁeld is good
ews—so good, in fact, that it presents a conundrum
or future studies. How does one demonstrate further
mprovements as the rate of adverse events declines? A
ecent study by Ayas et al. [19] highlights both the
ptimism and uncertainty that characterize the cur-
ent protocols. This study of 22 patients with matched
onors showed excellent results; however, the authors
oted that the optimal doses of cyclophosphamide and
TG remain unclear.
FA is a rare disease, and, consequently, many
ransplant series have been comparatively small. To
rove that a new conditioning regimen offers superior
urvival compared with the current regimens, our power
alculations suggest that centers may now need to use
he same protocol in multicenter collaborative studies.
In the literature, approximately half of reported
atients were in the high-risk group, deﬁned here as
atients without a matched sibling donor. This frac-
ion may be increasing over time. Clearly, reducing
he peritransplantation mortality rate in this group is
high priority. It is notable, therefore, that a study of
n  25 n  50 n  75 n  100 n  200
2.8* 2.0 1.7 1.6 1.4
5.2* 2.1 2.1 1.9 1.5
9.1* 18.2* 9.7 5.3 2.6
18.2* 5.2 3.3 2.6 1.9
18.4* 5.2 3.3 2.6 1.8
teness of the data, the magnitude of the detectable-fold reduction
s Who Received a Transplant, 1999-2004
Donor N† XRT FLU
atched 16 0 0
atched 27 22 0
atched 19 19 0
atched 37 37 0
atched 30 17 8
ismatched 29 29 0
ismatched 69 67 0
ismatched 8 8 8
ismatched 16 9 8
29 Matched 
122 mismatched 251 208 24
ed donors were reported in 28 publications. Five authors reported
eated here as separate studies.
ed conditioning with irradiation; FLU, the number who receivedive
e
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mo
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65 high-risk patients, each followed up for 6 months,
ould sufﬁce to detect a 2.8-fold reduction in peri-
ransplantation mortality with 80% power when the
ppropriate benchmark rate is 10%/month, corre-
ponding to a cumulative incidence of 45% at 6
onths. Eighty-four patients are needed when the
ppropriate benchmark rate is 5.5%/month. The 122
ismatched cases reported in 14 patient series or single
ase reports during 1999 to 2004 (Table 3) would have
een sufﬁcient to evaluate 2 or 3 promising protocols for
2- to 3-fold rate reduction, had it been possible to
nroll these patients in a few collaborative studies.
A multicenter study approach would have several
otential advantages. First, a sequence of nonrandom-
zed observational studies could be conducted [20],
ach sufﬁciently large to inform subsequent protocols.
he corresponding sample sizes required for random-
zed studies would be 4 times larger [13] and, there-
ore, difﬁcult or impossible to attain. Because the end
oints of development of severe aGVHD at 100 days
nd mortality at 6 months require only that each
atient be followed for up to 6 months, each trial
ould be completed soon after the target sample size
as enrolled. Second, ancillary questions might be
etter addressed by pooling resources and capabilities.
or example, a collaborative study could determine
hether the outcomes are associated with comple-
entation group, mutation status, or patient pheno-
ype. Third, results from a multicenter study might be
ore convincing and generalizable than pooled results
rom isolated studies, because the protocol itself
ould represent a consensus.
There are potential disadvantages. In the setting
f FA, some aspects of transplantation are as much art
s science. The astute clinician can make correct in-
ividualized decisions, and centers can incorporate
ew technology, ahead of deﬁnitive data. It is critical
hat common protocols do not blunt the art in an
ffort to advance the science. It is also critical that
nnovative ideas conceived by individual investigators
ontinue to be piloted. The conduct of a multicenter
tudy would also incur additional costs—for example,
o harmonize the study informatics and obtain ap-
roval by institutional review boards at dispersed in-
titutions. Funding sources will need to be convinced
f the value added.
Regardless of the protocol used, FA patients will
equire lifelong surveillance for cancer. Past trans-
lantation modalities increased the risk of solid tu-
ors above the high Fanconi baseline [5]. Even if new
rotocols were able to reduce the risk of solid tumors
o baseline, which is not clear, the cumulative inci-
ence of solid tumors would remain high and might
ctually increase over time, as more patients lived long
nough to develop tumors. The calculations in Table 2
uggest that to assess changes in cancer incidence will
equire long-term follow-up of essentially all FA patients
78ho receive a transplant. A registry for this purpose
ould be informative. A registry might also help to
uantify long-term outcomes in patients with matched
ibling donors, which requires even larger numbers.
In summary, this may be an appropriate time for
he ﬁeld to consider its strategies. Going forward, the
uestion is whether new protocols are to be evaluated
y small studies and retrospective analysis or by pro-
pective multicenter studies. The optimal strategy de-
ends on the expected size of the treatment effect. For
ffects in the range of a 2- to 3-fold risk reduction
elative to what has been achieved with recent proto-
ols, our sample size calculations suggest that the
atter approach is feasible and could answer key ques-
ions more quickly.
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